Home › Spinal Cord Injuries › NCT05018793

Safety of Cultured Allogeneic Adult Umbilical-cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for SCI

Safety of Cultured Allogeneic Adult Umbilical-cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Spinal Cord Injury

Who can join

All ages · All sexes

Inclusion Criteria:

* Diagnosis of Spinal Cord Injury
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Anticoagulation medicine use
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Previous organ transplant
* Hypersensitivity to sulfur
* Continued drug abuse
* Pre-menopausal women not using contraception

About the study

This trial will study the safety and efficacy of intrathecal injection of cultured allogeneic adult umbilical-cord or placental derived mesenchymal stem cells for the treatment of spinal cord injury

What is being tested

• Cultured Allogeneic Adult Umbilical-cord or Placental Derived Mesenchymal Stem Cell Intrathecal injection (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 15 · Started: Dec 1, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05018793

Locations in the U.S.

Conditions

• Spinal Cord Injuries

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.